Format

Send to

Choose Destination
See comment in PubMed Commons below
Yonsei Med J. 2007 Feb 28;48(1):1-10.

Therapeutic vaccine for lymphoma.

Author information

1
Department of Lymphoma and Myeloma, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030, USA.

Abstract

The unique antigenic determinants (Idiotype [Id]) of the immunoglobulin expressed on a given B-cell malignancy can serve as a tumor-specific antigen for active immunotherapy. Therapeutic vaccines targeting the tumor-specific idiotype have demonstrated promising results against lymphomas in phase I/II studies and are currently being evaluated in phase III randomized trials. Additional vaccine therapies being developed include those based on DNA, dendritic cells, gene-modified tumor cells. It is hoped that immunotherapeutic agents, used in tandem or in combination, may in the future allow effective treatment of lymphoid malignancies and delay or even replace the need for conventional cytotoxic therapies.

PMID:
17326239
PMCID:
PMC2628002
DOI:
10.3349/ymj.2007.48.1.1
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Yonsei University College of Medicine Icon for PubMed Central
    Loading ...
    Support Center